Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2015 - 2026)

Protalix BioTherapeutics' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $404000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 16.76% year-over-year to $404000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 14.68% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 12.35% from the prior year.
• Depreciation & Amortization (CF) advanced to $404000.0 in Q1 2026 per PLX's latest filing, from $387000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $404000.0 in Q1 2026 and bottomed at $268000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $319000.0 (2024), against an average of $321411.8.
• Across the five-year window, Depreciation & Amortization (CF) decreased 6.94% in 2022 and rose 16.76% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $289000.0 in 2022, then advanced by 8.3% to $313000.0 in 2023, then gained by 6.71% to $334000.0 in 2024, then advanced by 15.87% to $387000.0 in 2025, then grew by 4.39% to $404000.0 in 2026.
• Per Business Quant, the three latest PLX Depreciation & Amortization (CF) figures stand at $404000.0 (Q1 2026), $387000.0 (Q4 2025), and $372000.0 (Q3 2025).